Announced
Financials
Tags
Single Bidder
Private
Friendly
Majority
Pending
Biotechnology
Acquisition
United States
Domestic
biotechnology company
Synopsis
AbbVie, a firm that researches and develops pharmaceutical products, agreed to acquire Mitokinin, a developer of kinase-targeted neo-substrates intended to treat neurodegenerative and mitochondrial diseases. Financial terms were not disclosed. "It's a testament to the quality of our science and the strength of our scientific team that we were able to attract a partner of AbbVie's caliber. I'm excited to continue to demonstrate the therapeutic potential of our specific PINK1 targeting compounds and to push towards the clinic with the AbbVie team," Nicholas Hertz, Mitokinin Co-Founder and CSO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.